• 4683 Citations
  • 33 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

Neoplasms Medicine & Life Sciences
LY-2157299 Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Glioblastoma Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2019

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A. & 44 othersSkardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon Ahnert, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H. G., Singh-Jasuja, H., Sahin, U., Dietrich, P. Y. & Wick, W., Jan 10 2019, In : Nature. 565, 7738, p. 240-245 6 p.

Research output: Contribution to journalLetter

HLA Antigens
1 Citation (Scopus)

Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer

Meric-Bernstam, F., Johnson, A. M., Ileana Dumbrava, E. E., Raghav, K. P. S., Balaji, K., Bhatt, M., Murthy, R. K., Rodon Ahnert, J. & Piha-Paul, S. A., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2033-2041 9 p.

Research output: Contribution to journalReview article

Stomach Neoplasms
Breast Neoplasms
Biliary Tract Neoplasms

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Juric, D., Janku, F., Rodon Ahnert, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., Bootle, D., Demanse, D., Blumenstein, L., Schumacher, K., Huang, A., Quadt, C. & Rugo, H. S., Feb 1 2019, In : JAMA Oncology. 5, 2

Research output: Contribution to journalArticle

Estrogen Receptors
Clinical Trials
Breast Neoplasms
Maximum Tolerated Dose
Phosphatidylinositol 3-Kinase

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers (Nature, (2018), 554, 7691, (189-194), 10.1038/nature25475)

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon Ahnert, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J. & 27 othersBeer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J. & Solit, D. B., Feb 28 2019, In : Nature. 566, 7745, p. E11-E12

Research output: Contribution to journalComment/debate


Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Harding, J. J., Bauer, T. M., Tan, D. S. W., Bedard, P. L., Rodon Ahnert, J., Doi, T., Schnell, C., Iyer, V., Baffert, F., Radhakrishnan, R., Fabre, C. & Juric, D., Apr 15 2019, In : Investigational New Drugs. 37, 2, p. 271-281 11 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinases
Maximum Tolerated Dose